Skip to main content
NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
21.76
-0.65 (-2.90%)
At close: Mar 28, 2025, 4:00 PM
20.86
-0.90 (-4.13%)
Pre-market: Mar 31, 2025, 7:40 AM EDT

NAMS Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
45.5614.09102.69--
Revenue Growth (YoY)
223.37%-86.28%---
Gross Profit
45.5614.09102.69--
Selling, General & Admin
70.4537.6319.5161.38
Research & Development
151.41159.4286.7428.974.05
Operating Expenses
221.85197.06106.2534.985.43
Operating Income
-176.29-182.97-3.56-34.98-5.43
Interest Expense
---0.29-0.41-0.34
Interest & Investment Income
16.8811.28---
Currency Exchange Gain (Loss)
-6.65.06-9.751.710.02
Other Non Operating Income (Expenses)
-38.58-10.02-8.34-7.22-
EBT Excluding Unusual Items
-204.59-176.64-21.93-40.9-5.75
Other Unusual Items
-37.01-0.27-0.71-0.88-
Pretax Income
-241.6-176.91-22.63-41.79-5.75
Income Tax Expense
-00.03---
Net Income
-241.6-176.94-22.63-41.79-5.75
Net Income to Common
-241.6-176.94-22.63-41.79-5.75
Shares Outstanding (Basic)
948219115
Shares Outstanding (Diluted)
948219115
Shares Change (YoY)
14.84%333.20%72.75%119.58%-
EPS (Basic)
-2.56-2.15-1.19-3.81-1.15
EPS (Diluted)
-2.56-2.15-1.19-3.81-1.15
Free Cash Flow
-159.24-141.2410.44-29.54-5.98
Free Cash Flow Per Share
-1.69-1.720.55-2.69-1.20
Gross Margin
100.00%100.00%100.00%--
Operating Margin
-386.91%-1298.56%-3.46%--
Profit Margin
-530.25%-1255.76%-22.04%--
Free Cash Flow Margin
-349.49%-1002.43%10.17%--
EBITDA
-176.18-182.92-3.55-34.97-5.43
EBITDA Margin
---3.45%--
D&A For EBITDA
0.110.050.010.010
EBIT
-176.29-182.97-3.56-34.98-5.43
EBIT Margin
---3.46%--
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q